Iveric Bio   Report issue

For profit Phase 1 Phase 3
Founded: Princeton NJ United States (2007)
Status: Acquired by Astellas (2023) → now Leo Pharma (2015)

Organization Overview

First Clinical Trial
2007
NCT00569140
First Marketed Drug
2023
avacincaptad pegol (Izervay)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

IVERIC BIO | IVERIC bio, Inc. | IVERIC BIO, INC. | Ophthotech Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 3)

Geographic Atrophy (Phase 3)

Macular Degeneration (Phase 3)

Vascular Diseases (Phase 2)

Wet Macular Degeneration (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 7